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High levels of C-reactive protein and soluble intercellular adhesion molecule 1 
are associated with increased risk for cardiovascular events. No long-term data 
is available on predictive value of preoperative C-reactive protein and soluble 
intercellular adhesion molecule 1 on the outcome after coronary artery bypass 
grafting. We measured baseline C-reactive protein and soluble intercellular 
adhesion molecule 1 in preoperative serum stored at -80°C of 87 coronary artery 
diseased patients before undergoing isolated coronary artery bypass grafting. 
Follow up was performed after a mean duration of 7.6±0.1 years and all 
cardiovascular events were recorded. Data were analyzed by dividing the 
patients into two groups according to the median value of C-reactive protein and 
soluble intercellular adhesion molecule 1. During follow up 16 patients 
experienced a cardiovascular event. In patients with C-reactive protein above 
the median (1.9 mg/L) the cumulative cardiovascular event incidence was 29% 
compared to 9% in patients below the median (P=0.048). In Cox-regression 
analysis, corrected for age, gender and conventional risk factors, the adjusted 
relative risk of cardiovascular events of C-reactive protein above median was 3.9 
(95% CI, 1.1 to 13.9; P<0.05). soluble intercellular adhesion molecule 1 level 
above the median (136μg/L) was associated with a cumulative cardiovascular 
event incidence of 21% versus 16% below the median (P=0.48). In conclusion, 
in patients undergoing coronary artery bypass grafting, elevated preoperative C-
reactive protein levels, but not soluble intercellular adhesion molecule 1 levels, 
were associated with long term risk of cardiovascular events, independent of 









C-reactive protein has emerged as an important predictor of cardiovascular 
events in apparently healthy subjects1;2, but also in patients with myocardial 
infarction3, stable or unstable angina and after coronary conventional balloon 
angioplasty4 or stent implantation.5 Elevated levels of preoperative C-reactive 
protein has been associated with postoperative, in-hospital, outcome after 
coronary artery bypass grafting.6 However, no data is available on long-term 
outcome after coronary artery bypass grafting. Cellular adhesion molecules, 
expressed on the endothelial membrane, facilitate the adhesion and subsequent 
transendothelial migration of circulating leukocytes. Soluble intercellular 
adhesion molecule 1 can be found in plasma and is considered to be surrogate 
markers of their true endothelial expression. Indeed, in healthy men, soluble 
intercellular adhesion molecule 1 has been associated with risk of future 
myocardial infarction.1;7 However, the value of soluble intercellular adhesion 
molecule 1 in patients with established coronary artery disease remains to be 
determined. In this report, we analyzed the predictive value of preoperative C-
reactive protein and soluble intercellular adhesion molecule 1 levels on long term 
incidence of cardiovascular events in patients undergoing coronary artery bypass 
grafting.  
Methods and Results 
From 1994 to 1997, 187 patients underwent elective coronary artery bypass 
grafting and participated in the QUO VADIS study.8 Data on preoperative 
concentrations of C-reactive protein and soluble intercellular adhesion molecule 
1 were available in 87 patients who form the basis of the present study.9 
Selection of the patients in the present study was solely based on the availability 
of serum (at -80°C) to determine preoperative C-reactive protein and soluble 
intercellular adhesion molecule 1. The institutional review board approved this 
study, and written informed consent was obtained from each subject. All 
laboratory measures were made in a core facility, and a validated assay was 
used for high sensitive C-reactive protein and soluble intercellular adhesion 
molecule 1.9  
Long-term follow-up was performed by telephone contact. All cardiovascular 
events were validated by review of medical records. The outcome measure 
assessed was the time from coronary artery bypass grafting until the first 
occurrence of a component of the following: cardiovascular death, 
hospitalization for myocardial infarction, revascularization with percutaneous 
coronary intervention or re-coronary artery bypass grafting (if these procedures 
were performed at least 30 days after randomization), vascular surgery, and 
stroke as described previously.10 
Data are expressed as mean±SEM. Statistical significance of differences in 
baseline characteristics was assessed by unpaired Student t test or χ2 test when 






Table 1. Distribution of baseline characteristics by baseline C-reactive protein 
and soluble intercellular adhesion molecule 1 concentrations 
 C-reactive protein Soluble intercellular adhesion molecule 1 







Age, (years) 62.9±1.5 62.9±1.2 1.0 62.3±1.4 63.5±1.3 0.53 
Male/female 37/7 37/6 0.80 39/5 35/8 0.35 
Body mass index (kg/m2) 25.6±0.4 27.1±0.5 0.01 26.3±0.4 26.4±0.4 0.87 
Hypertension 26 21 0.24 21 25 0.33 
Diabetes Mellitus 3 6 0.28 3 6 0.28 
Smoker   0.01   0.48 
      Never smoked 11 5  8 8  
      Current smoker 4 12  6 10  
Number of coronary arteries 
narrowed 
  0.67   0.32 
   1 3 2  2 3  
   2 12 11  10 13  
   3 29 30  32 27  
NYHA class >II 23 23 0.90 22 24 0.40 
Prior angina pectoris 
(past/current) 
4/40 2/41 0.42 2/42 4/39 0.38 
Prior myocardial infarction 17 19 0.60 16 20 0.34 
Prior percutaneous coronary     
Intervention 
6 5 0.78 8 3 0.12 
Heart rate (bpm) 70.9±1.7 72.4±1.8 0.55 68.6±1.5 74.8±1.9 0.01 
Blood pressure (mm Hg)       
   Systolic  139.0±2.8 136.2±3.0 0.50 137.7±3.2 137.4±2.6 0.95 
   Diastolic 79.3±1.3 78.3±1.2 0.57 79.2±1.3 78.3±1.2 0.60 
Lipid concentrations (mmol/l 
[mg/dl]) 
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Medication       
   Quinapril 20 22 0.60 16 26 0.03 
   Aspirin 38 32 0.16 37 37 0.75 
   Lipid lowering 18 18 0.93 19 17 0.73 
Follow-up time (years) 7.4±0.2 7.8±0.2 0.79 7.6±0.2 7.5±0.2 0.41 
 
 
appropriate. Cox proportional hazards multivariate stepwise regression analysis 
was used to compute hazard ratios as estimates of relative risk of C-reactive 
protein and cardiovascular events during the follow-up period. Covariates 
entered in this regression model were age, sex, diabetes, hypertension, number 
of diseased coronary vessels, smoking status, body mass index, total cholesterol 
and high-density lipoprotein cholesterol. Statistical analysis was performed with 
SPSS statistical software (SPSS, Chicago, IL, USA). All P values were 2-tailed, 







Of the 87 patients, 1 patient was lost to follow-up. Age at baseline was 62.9±0.9 
years, and 13 (15%) were women. Before coronary artery bypass grafting, 41% 
of patients had a history of myocardial infarction, and 13% had previously 
undergone a percutaneous coronary intervention. At baseline, total cholesterol 
was 6.3±0.1 mmol/L (242 mg/dL), low-density lipoprotein cholesterol was 
4.2±0.12 mmol/L (164 mg/dL), high-density lipoprotein cholesterol was 
1.03±0.03 mmol/L (40 mg/dL), and triglycerides 2.09±0.15 mmol/L (195 
mg/dL). Mean duration of follow-up was 7.6±0.14 years (median 7.7 years).  
The median C-reactive protein was 1.9 mg/L (interquartile range 0.9 to 4.7 
mg/L), the median soluble intercellular adhesion molecule 1 was 136 μg/L 
(mean 149±12). Baseline characteristics according to median C-reactive protein 
and soluble intercellular adhesion molecule 1 are presented in Table 1.  High C-
reactive protein was associated with higher body mass index and smoking (table 
2). High soluble intercellular adhesion molecule 1 was only associated with a 
small increase in average heart rate.  
During follow-up, 16 (19%) experienced a cardiovascular event, and 2 of these 
subjects had 2 events (Table 2). With C-reactive protein levels above the 
median (1.9 mg/L) the cumulative event incidence was 29% compared to 9% in 
patients below the median (P=0.048). C-reactive protein below median was 
associated with 69% fewer events (P<0.05). The relative risk for C-reactive 
protein above median was 3.1 (P<0.05). The age-, and sex-adjusted relative 
risk of cardiovascular events for C-reactive protein above median was 3.4 and 
after adjusting for conventional risk factors increased the relative risk to 3.8 
(table 3). Figure 1 shows the 7.7 years age-, and sex-adjusted cumulative event 
rate for C-reactive protein and soluble intercellular adhesion molecule 1. When 
only the more objective events (cardiac death, myocardial infarction, and 
stroke) were considered, C-reactive protein above median remained a moderate 
predictor (relative risk 4.3 [95% CI, 0.75 to 24.55; P=0.10) with adjustment for 
age-, sex- and conventional risk factors. 
With soluble intercellular adhesion molecule 1 levels above the median (136 
ug/L) the cumulative event incidences were 21% and with soluble intercellular 
adhesion molecule 1 below median 16% (non-significant difference).  
Cumulative cardiovascular event rate. Sex and age adjusted hazard ratios are shown for A) C-reactive protein 
(P<0.05) and B) soluble intercellular adhesion molecule 1 (P=NS) above and below its median value. 
 Figure 1.  






Table 2. Index of Cardiovascular Events During Follow-Up 
  C-reactive protein   
Soluble intercellular adhesion 
molecule 1 
Outcome All patients Low High P-value Low High P-value 
Cardiac death 1 1  0.617 1  0.414 
Myocardial infarction 2  2 0.532 1 1 0.595 
Percutaneous coronary 
intervention 
2  2 0.138  2 0.138 
Re- coronary artery bypass 
grafting 
1 1  0.337  1 0.298 
Stroke 8 2 6 0.108 4 4 0.905 
Vascular surgery 4  4 <0.001 3 1 0.350 
Total events 16 4 12 0.021 7 9 0.582 
 
Discussion 
In this 7.6 years study in coronary artery bypass graft patients, we studied the 
association between the inflammatory markers C-reactive protein and soluble 
intercellular adhesion molecule 1 with future cardiovascular events. Stratification 
according to preoperative soluble intercellular adhesion molecule 1 was not 
associated with an increase in cardiovascular events in our patients. However, 
we must be cautious in concluding lack of relation considering our sample size. 
In contrast to soluble intercellular adhesion molecule 1, cardiovascular event 
rate was significantly increased in patients with a preoperative C-reactive 
protein level above the median of 1.9 mg/L. Increased preoperative C-reactive 
protein was associated with 3-fold increased risk for cardiovascular events, even 
after adjustment for conventional risk factors.  
 
Table 3. Relative risk of preoperative levels of C-reactive protein and soluble 
intercellular adhesion molecule 1 above median for cardiovascular events 
C-reactive protein Soluble intercellular adhesion molecule 1  
RR 95%CI P-value RR 95%CI P-value 
Univariate 3.14 1.01-9.86 0.048 1.43 0.53-3.84 0.48 
Model 1 3.44 1.09-10.84 0.035 1.39 0.52-3.74 0.51 
Model 2 3.84 1.04-14.2 0.043 1.59 0.53-4.77 0.41 
Model 1 is adjusted for age and sex. Model 2 is adjusted for age, sex, diabetes, hypertension, number of diseased 
coronary vessels, smoking status, body mass index, total cholesterol, and high-density lipoprotein cholesterol. 
 
The predictive value of C-reactive protein for recurrent cardiovascular events 
and death has been established previously in apparently healthy subjects1;2 and 
in patients with acute coronary syndromes11 or stroke12, among patients in the 
stable phase after myocardial infarction3, and among patients with documented 







predominantly 3-vessel, coronary artery disease, in patients undergoing 
coronary artery bypass grafting, patients with increased C-reactive protein have 
an increased long-term risk of cardiovascular events. Previously, predictive 
value of C-reactive protein for in-hospital death after coronary artery bypass 
grafting was reported by others. Gaudino et al suggested that C-reactive protein 
>5.0 mg/L was not associated with in-hospital outcome in 113 coronary artery 
bypass graft patients14. However, Biancari et al reported a larger serie, involving 
764 patients, in which they did find preoperative serum C-reactive protein levels 
of  >1.0 mg/L to be associated with a significant increased risk of postoperative 
in-hospital death.6 In addition, Milazzo et al reported that coronary artery 
bypass graft patients with preoperative serum C-reactive protein level of >0.3 
mg/L had a significant increased risk to experience late ischemic events during a 
mean follow-up of 3.2 years.15 Unfortunately, they did not correct for other risk 
factors. Preprocedural C-reactive protein has also been reported to predict 
cardiovascular events in other settings, including conventional balloon 
angioplasty4 and coronary artery stent implantation5. Our median value of 1.9 
mg/L is very close to the frequently used C-reactive protein cut-off value of 2.0 
mg/L.11;16 Our data suggests that preoperative C-reactive protein assessment 
might identify those at increased risk after surgery to experience another 
cardiovascular event.  
Limitations of this study include its small sample size and will therefore require 
confirmation in larger prospective investigations. We studied only a limited 
number of patients and might have been underpowered to detect the prognostic 
importance of soluble intercellular adhesion molecule 1. Further work is needed 
to validate our findings in appropriate powered studies and to determine the 
appropriate values defining elevated C-reactive protein in this patient group. 
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